Abiopharma

🔍 Bergman Alan B. (Executive)

Company: 20/20 Biolabs, Inc. (AIDX)

Report Date: 2026-04-02

Detailed Transactions and Holdings:

• Acquired 100,000 shares of Stock Option at $1.88 per share (Derivative)
  Date: 2026-04-02 | Code: A | Expires: 2036-04-02 | equity_swap_involved: 0 | shares_owned_after: 100,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: 25,000 of the shares subject to the stock option will vest on the first anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer.